deferoxamine has been researched along with razoxane in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bast, A; van Acker, SA; van Asbeck, BS; van der Vijgh, WJ; Voest, EE | 1 |
| Ferrans, VJ; Herman, EH; Zhang, J | 1 |
| Hider, RC; Tilbrook, GS | 1 |
| Anandasbapathy, S; Elihu, N; Frishman, WH | 1 |
| Boehme, P; Gordeuk, VR; John, C; Loyevsky, M; Sacci, JB; Weglicki, W | 1 |
| Huang, F; Tang, LH | 1 |
| Bast, A; den Hartog, GJ; Kaiserová, H; Kvasnicková, E; Schröterová, L; Simůnek, T | 1 |
3 review(s) available for deferoxamine and razoxane
| Article | Year |
|---|---|
Iron chelators for clinical use.
Topics: Biological Transport; Deferoxamine; Drug Delivery Systems; Edetic Acid; Ferric Compounds; Free Radical Scavengers; Humans; Iron; Iron Chelating Agents; Iron Overload; Ligands; Molecular Weight; Oxidation-Reduction; Pentetic Acid; Razoxane; Solubility; Structure-Activity Relationship; Tissue Distribution | 1998 |
Chelation therapy in cardiovascular disease: ethylenediaminetetraacetic acid, deferoxamine, and dexrazoxane.
Topics: Antibiotics, Antineoplastic; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Deferoxamine; Doxorubicin; Edetic Acid; Female; Humans; Iron; Razoxane | 1998 |
[Research progress on iron chelator for malaria therapy].
Topics: Animals; Antimalarials; Deferoxamine; Humans; Iron Chelating Agents; Malaria; Razoxane | 2005 |
4 other study(ies) available for deferoxamine and razoxane
| Article | Year |
|---|---|
Comparison of different iron chelators as protective agents against acute doxorubicin-induced cardiotoxicity.
Topics: Animals; Atrial Function; Cyclic N-Oxides; Deferoxamine; Doxorubicin; Drug Evaluation, Preclinical; Edetic Acid; Heart; Heart Atria; Hydrogen Peroxide; In Vitro Techniques; Iron Chelating Agents; Male; Mice; Mice, Inbred BALB C; Myocardial Contraction; Pyridones; Razoxane | 1994 |
Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cardiomyopathies; Deferoxamine; Doxorubicin; Heart Rate; Injections, Intraperitoneal; Injections, Intravenous; Kidney Diseases; Male; Rats; Rats, Inbred SHR; Razoxane | 1994 |
Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures.
Topics: Animals; Cells, Cultured; Chromatography, High Pressure Liquid; Deferoxamine; Erythrocytes; Ethylenediamines; Ferrous Compounds; Fluoresceins; Fluorescent Dyes; Glycine; Humans; Iron Chelating Agents; Liver; Malaria, Falciparum; Mice; Microscopy, Fluorescence; Parasitemia; Plasmodium falciparum; Plasmodium yoelii; Prodrugs; Quaternary Ammonium Compounds; Razoxane; Spectrometry, Fluorescence; Surface Properties | 1999 |
Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.
Topics: Aldehydes; Antibiotics, Antineoplastic; Apoptosis; Bleomycin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deferoxamine; Doxorubicin; Electron Spin Resonance Spectroscopy; Free Radicals; Humans; Hydrazones; Hydrogen Peroxide; Iron; Iron Chelating Agents; Iron Compounds; Isoniazid; Lipid Peroxidation; Lung Neoplasms; Oxidative Stress; Pyridoxal; Razoxane; Time Factors | 2006 |